COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2

Document text

Principal Investigator: Matthew  Hall
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2020
Award: $859,275
Funding agency: National Center for Advancing Translational Sciences

During this past reporting period, NCATS began development of over a dozen novel assays to screen for potential therapeutic agents against SARS-CoV-2.  Optimized assays were then screened against a panel of drug repurposing, clinical candidate and antiviral libraries that have been assembled at NCATS.  These results have been made freely available to public with unprecedented speed through the NCATS OpenData Portal and through a number of preprint/journal publications.

These assays include both virus (e.g. Spike protein) and host (e.g. ACE2, TMPRSS) targets, as well as BSL3 live SARS-CoV-2 virus infectivity assays accessed through research contracts.  Many assays have been solely developed in-house at NCATS, while a number of others have been designed in collaboration with both intramural and extramural laboratories with subject area expertise.  

These collaborations include:
1. Cell-based SARS-CoV-2 ORF3a assay with Dr. Michael Lenardo (NIAID)
2. Recombinant SARS-CoV-2 nsp13 helicase assay with Dr. Robert Brosh (NIA)
3. Cell-based DNA topoisomerase assay with Dr. Yves Pommier (NCI)
4. Combination screening with Dr. Eugene Muratov (University of North Carolina)

Terms: <2019 novel coronavirus><2019-nCoV><Address><Antiviral Agents><Antiviral Drugs><Antivirals><Area><Assay><Bioassay><Biologic Assays><Biological Assay><Biology><COVID><COVID-19><COVID19><Cell Body><Cells><Clinical><CoV disease><Collaborations><Communities><Coronaviridae><Coronavirus><DNA Helicases><DNA Topoisomerases><DNA Unwinding Proteins><DNA unwinding enzyme><Data><Development><Disease><Disorder><Drugs><EXTMR><Extramural><Extramural Activities><Goals><High Throughput Assay><Infectious Agent><Investigators><Journals><Knowledge><Laboratories><Libraries><Magazine><Medication><Mind><NIAID><National Institute of Allergy and Infectious Disease><North Carolina><Pharmaceutic Preparations><Pharmaceutical Preparations><Position><Positioning Attribute><Proteins><Protocol><Protocols documentation><Public Health><Publications><Recombinants><Reporting><Research><Research Activity><Research Contracts><Research Personnel><Research Resources><Research Support><Researchers><Resources><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Scientific Publication><Screening Result><Severe acute respiratory syndrome coronavirus 2><Site><Societies><Speed><Testing><Therapeutic><Therapeutic Agents><Therapeutic Intervention><Translational Research><Translational Science><Translations><Universities><Vaccines><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-virals><assay development><atypical pneumonia><base><clinical candidate><clinical efficacy><corona virus><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><design><designing><developmental><drug/agent><effective therapy><effective treatment><helicase><high throughput screening><infectious organism><intervention therapy><novel><pandemic><pandemic disease><screening><therapeutic agent development><therapeutic development><translation research><viral infection><virus infection><virus-induced disease>